argus

ALEMBIC PHARMACEUTICALS LIMITED

NSE: APLLTDINE901L0101816,596 Cr

Timeline

Time (IST)TypeMEventSrc
06 Apr, 02:38 pmAlembic Pharmaceuticals Ltd - 533573 - Dislcosure letter under Regulation 11(5) of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.bse
01 Apr, 07:07 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
01 Apr, 07:03 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Cessationbse
01 Apr, 06:57 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
01 Apr, 06:41 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr. Chirayu Amin as Executive Chairman of the company w.e.f. April 01, 2026.nse
01 Apr, 06:38 pmAlembic Pharmaceuticals Limited has informed the Exchange that Mr. Chirayu Amin has Relinquished the position of Chief Executive Officer of the company w.e.f. April 01, 2026.nse
01 Apr, 06:25 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Re-Appointment of Mr. Pranav Amin as Managing Director of the company w.e.f. April 01, 2026.nse
01 Apr, 02:15 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
01 Apr, 02:11 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr. Rajkumar Baheti as Non- Executive Non Independent Director of the company w.e.f. April 01, 2026.nse
31 Mar, 08:58 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Managementbse
31 Mar, 08:57 pmAlembic Pharmaceuticals Limited has informed the Exchange about change in Managementnse
27 Mar, 03:22 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
27 Mar, 03:19 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg.".nse
09 Mar, 07:51 pmAlembic Pharmaceuticals Limited has informed the Exchange about General Updates - Incorporation of Subsidiarynse
09 Mar, 07:49 pmAlembic Pharmaceuticals Ltd - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Incorporation Of Subsidiarybse
06 Mar, 09:05 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 06, 2026, titled "Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch through Alembic Therapeutics LLC".nse
06 Mar, 09:03 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
26 Feb, 10:44 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg".nse
26 Feb, 10:42 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
24 Feb, 02:30 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
24 Feb, 02:29 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".nse
18 Feb, 10:59 pmCompletion of United States Food and Drug Administration inspection atAlembic Pharmaceuticals Limited Injectable Facility (F-3) at Karakhadinse
11 Feb, 07:11 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
11 Feb, 07:06 pmAlembic Pharmaceuticals Limited has informed the Exchange about Transcriptnse
06 Feb, 11:31 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets.".nse
06 Feb, 11:31 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
05 Feb, 07:26 pmAlembic Pharmaceuticals Limited has informed the Exchange about Link of Recordingnse
05 Feb, 07:26 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
05 Feb, 04:15 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
05 Feb, 03:57 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr. Raj Kumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director of the company w.e.f. April 01, 2026.nse
05 Feb, 03:12 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
05 Feb, 03:12 pmAlembic Pharmaceuticals Limited has informed the Exchange about Investor Presentationnse
05 Feb, 02:22 pmAlembic Pharmaceuticals Ltd - 533573 - Unaudited Financial Results For Quarter And Nine Months Ended 31St December, 2025bse
05 Feb, 02:16 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
05 Feb, 02:13 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
05 Feb, 02:08 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Press Release on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025".nse
05 Feb, 02:04 pmAlembic Pharmaceuticals Limited has informed the Exchange about Investor Presentationnse
05 Feb, 02:00 pmAlembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.nse
05 Feb, 02:00 pmAlembic Pharmaceuticals Ltd - 533573 - Board Meeting Outcome for Outcome Of Board Meetingbse
05 Feb, 01:57 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 05, 2026.nse
31 Jan, 07:08 pmAlembic Pharmaceuticals Limited has informed the Exchange about change in Managementnse
31 Jan, 07:08 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Managementbse
27 Jan, 12:36 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
27 Jan, 12:36 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".nse
20 Jan, 10:28 amAlembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2025bse
12 Jan, 12:10 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 12, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for BosutinibTablets, 400 mg".nse
12 Jan, 12:07 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Dec, 11:02 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Travoprost Ophthalmic Solution".nse
18 Dec, 11:00 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
16 Dec, 04:03 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse